MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
about
Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspectiveUtility of diffusion-weighted imaging to assess hepatocellular carcinoma viability following transarterial chemoembolization.Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response.Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective.Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)Imaging of hepatocellular carcinoma and image guided therapies - how we do it.The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.Peri-intraprocedural imaging: US, CT, and MRI.Imaging of HCC.Imaging appearance of treated hepatocellular carcinomaContrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study.Hepatic imaging following intra-arterial embolotherapy.Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization.MR-PET evaluation of 1-month post-ablation therapy for hepatocellular carcinoma: preliminary observations.Magnetic resonance-imaging of the effect of targeted antiangiogenic gene delivery in a melanoma tumour model.Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy.Locoregional therapy-induced tumor necrosis as a predictor of recurrence after liver transplant in patients with hepatocellular carcinoma.Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE.Detection of recurrent hepatocellular carcinoma on post-operative surveillance: comparison of MDCT and gadoxetic acid-enhanced MRI.GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot studyUsefulness of fusion images of unenhanced and contrast-enhanced arterial phase cone-beam CT in the detection of viable hepatocellular carcinoma during transarterial chemoembolizationContrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following Transarterial Chemoembolization: Is It Helpful for Tumor Response?Quantitative portal vein velocity of liver cancer patients with transcatheter arterial chemoembolization on angiography
P2860
Q28080761-57ECF969-AEDF-4728-9100-F066A97F6174Q33843274-428238DF-4CBD-491B-AB51-A194EB014982Q34065128-FEDBD059-9D1A-4388-9587-DA535DA0E305Q35383390-1D794CB5-C2A8-42D7-B4FC-1310F848948AQ36307995-A765DCD4-8CFC-4570-B915-D54813CC8824Q36423114-E1F5050B-20C0-4291-841B-62BCB364C803Q37680183-D8252C0C-7F4B-49B0-B562-FED6788F367FQ37738796-903F3C1C-EFD9-4EA8-A067-8137F9A11D83Q37876333-42BCB06E-D090-4FE1-84FD-8B4B9B09756BQ37930465-A89211D5-7A94-486F-8D6F-DB05C0E5E8D3Q38136207-516A74C5-174E-4BA8-B9D3-9105083D3841Q38441813-73D0589B-6D76-4BDC-8279-266A28E55548Q38716483-71E479D3-5BC4-471B-A314-1DC3DB182A7DQ40921461-7F9D04BE-29D9-4715-990E-1A8750DD506AQ41022854-A07E95B7-10A3-4A93-96F2-B1C6A0F47D8BQ45870579-38EAC3A3-E3D3-40AF-9748-2B356600CCEEQ46086197-83F67E02-4748-49A7-8099-F0501B705A9DQ51030210-F463272F-1DEC-4ACB-A017-99A442D0A0AAQ52985675-1B9AD83D-C94D-4ED1-A5A4-DF039B0E7463Q53084289-850A4CF1-8B98-4963-AB0E-34389A7821C8Q53178946-5CCE5114-7E8F-4261-B2AB-675E5972D90CQ53246536-2E7EA0A9-51EF-4946-AC6D-84BE4106112EQ57168139-BAFF2E4D-9F82-4C97-87C0-7025E8D66BB7Q58775293-1DC3C2DF-87F0-4BD4-8AA3-9E2AC2379F54Q58802980-52054D74-77A2-44E7-B4B7-BF00BC3855FAQ58915077-9F88608D-5600-49EA-81A8-7A7B349582D7
P2860
MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@en
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@nl
type
label
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@en
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@nl
prefLabel
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@en
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@nl
P2093
P1476
MDCT versus MRI assessment of ...... t of hepatocellular carcinoma.
@en
P2093
Christoph Dueber
Katja Oberholzer
Michael B Pitton
Stefan Biesterfeld
P2888
P304
P356
10.1007/S00270-009-9728-Y
P577
2009-10-22T00:00:00Z
P5875
P6179
1032941862